EA201890618A1 - Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами - Google Patents

Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами

Info

Publication number
EA201890618A1
EA201890618A1 EA201890618A EA201890618A EA201890618A1 EA 201890618 A1 EA201890618 A1 EA 201890618A1 EA 201890618 A EA201890618 A EA 201890618A EA 201890618 A EA201890618 A EA 201890618A EA 201890618 A1 EA201890618 A1 EA 201890618A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
methods
anomatic
treatment
cocrystal
Prior art date
Application number
EA201890618A
Other languages
English (en)
Russian (ru)
Inventor
Гари Д. Глик
Луиджи Франки
Original Assignee
Ферст Вэйв Байо, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ферст Вэйв Байо, Инк. filed Critical Ферст Вэйв Байо, Инк.
Publication of EA201890618A1 publication Critical patent/EA201890618A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
EA201890618A 2015-09-01 2016-09-01 Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами EA201890618A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562213016P 2015-09-01 2015-09-01
US201562241508P 2015-10-14 2015-10-14
PCT/US2016/050012 WO2017040864A1 (en) 2015-09-01 2016-09-01 Methods and compositions for treating conditions associated with an abnormal inflammatory responses

Publications (1)

Publication Number Publication Date
EA201890618A1 true EA201890618A1 (ru) 2018-10-31

Family

ID=58097295

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890618A EA201890618A1 (ru) 2015-09-01 2016-09-01 Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами

Country Status (21)

Country Link
US (11) US10292951B2 (enExample)
EP (1) EP3344274A4 (enExample)
JP (2) JP6955648B2 (enExample)
KR (1) KR20180080189A (enExample)
CN (1) CN109562137A (enExample)
AU (2) AU2016315852B2 (enExample)
BR (1) BR112018004069A2 (enExample)
CA (1) CA2997136A1 (enExample)
CL (1) CL2021000622A1 (enExample)
CO (1) CO2018003465A2 (enExample)
CR (1) CR20180185A (enExample)
EA (1) EA201890618A1 (enExample)
HK (1) HK1258048A1 (enExample)
IL (1) IL257801A (enExample)
MX (3) MX2018002586A (enExample)
PE (1) PE20181295A1 (enExample)
PH (1) PH12018500448A1 (enExample)
SG (1) SG10201914118SA (enExample)
TN (1) TN2018000069A1 (enExample)
UA (1) UA125747C2 (enExample)
WO (1) WO2017040864A1 (enExample)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
CA3012229C (en) 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
ES2661000T3 (es) 2014-09-12 2018-03-27 Antibiotx A/S Uso antibacteriano de salicilanilidas halogenadas
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN104880428B (zh) * 2015-06-23 2016-07-06 山西振东安特生物制药有限公司 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
CN108472245A (zh) * 2015-11-04 2018-08-31 因赛特公司 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
US11278551B2 (en) 2017-03-15 2022-03-22 Georgetown University Treating cancer with a CCK receptor inhibitor and an immune checkpoint inhibitor
BR112019019519A2 (pt) 2017-03-21 2020-04-22 Novalead Pharma Inc agente terapêutico para a inibição de fosfodiesterase e seus distúrbios relacionados
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
KR102459936B1 (ko) * 2017-10-13 2022-10-27 주식회사 엘지생활건강 알칸닌을 포함하는 구강질환 예방 또는 치료용 조성물
WO2019126739A1 (en) 2017-12-21 2019-06-27 Shepherd Therapeutics, Inc. Pyrvinium pamoate anti-cancer therapies
EP3773579A4 (en) 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
BR112021000021A2 (pt) 2018-07-03 2021-03-30 Fennec Pharmaceuticals, Inc. Tiossulfato de sódio anidro e formulações do mesmo
IL261670B (en) * 2018-09-06 2019-06-30 Tudu Holdings Ltd Magnesium-containing formulation and uses thereof
CN109180600A (zh) * 2018-09-21 2019-01-11 五邑大学 一种麝香草酚类似物及其应用
PT3856182T (pt) * 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
MA54089A (fr) * 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
MX428309B (es) * 2019-03-22 2025-11-13 Mannkind Corp Polvos secos inhalables
US20220193028A1 (en) * 2019-04-18 2022-06-23 Prevep Llc Therapeutic combinations, liquid pharmaceutical compositions, kits for their preparation, and methods of their use
CN111032030B (zh) * 2019-04-28 2023-02-17 深圳市中医院 氯硝柳胺乙醇胺盐在制备治疗系统性红斑狼疮及其并发症的药物中的应用
CN112007036B (zh) * 2019-05-29 2022-01-21 百岳特生物科技（上海）有限公司 化合物及其组合物用于制备缓解肺上皮细胞发炎的医药品的用途
CN110200935B (zh) * 2019-06-03 2021-03-02 浙江得恩德制药股份有限公司 一种胶体果胶铋胶囊及其制备工艺
JP6622950B1 (ja) * 2019-07-08 2019-12-18 株式会社Moresco マイクロエマルションを調製するための組成物、マイクロエマルション、これらの製造方法、及びマイクロエマルションの利用
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
ES2913792T3 (es) * 2019-09-03 2022-06-06 Square Power Ltd Rebamipida para uso en la profilaxis y el tratamiento de la enfermedad celíaca
US20210114973A1 (en) * 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
KR102300846B1 (ko) * 2019-11-01 2021-09-09 서울대학교산학협력단 면역 활성 개선용 조성물 및 이의 방법
CN111122523B (zh) * 2019-12-06 2021-09-28 山西大学 一种快速识别Ag+和Cys的三相输出功能的分子逻辑门及其构建方法
US20230102999A1 (en) 2020-01-10 2023-03-30 First Wave Bio, Inc. Deuterated niclosamide
WO2021142240A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Compositions comprising niclosamide for use in treating conditions associated with an abnormal inflammatory response
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
TW202200121A (zh) 2020-03-16 2022-01-01 美商費斯特威弗生技股份有限公司 治療方法
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115484985A (zh) * 2020-03-19 2022-12-16 崔泽尔有限公司 温度响应病毒储存系统
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CN112914547A (zh) * 2020-03-22 2021-06-08 复旦大学附属华山医院 内源性神经干细胞磁共振无创性示踪技术体系及建立方法
CN115701983A (zh) * 2020-04-01 2023-02-14 联合治疗股份公司 配制品
US11045434B1 (en) * 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease
WO2021226256A1 (en) * 2020-05-05 2021-11-11 Neurobo Pharmaceuticals, Inc. Niclosamide formulations and methods of use
US12589104B2 (en) 2020-05-13 2026-03-31 The Regents Of The University Of California Thiosaccharides for use in treating coronavirus infection
WO2021231421A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus
CN112057623A (zh) * 2020-06-03 2020-12-11 江苏靶标生物医药研究所有限公司 一种磷脂酰丝氨酸在制备治疗炎症性肠病药物中的应用
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
WO2021255218A1 (en) * 2020-06-19 2021-12-23 Charité - Universitätsmedizin Berlin A pharmaceutical combination comprising an anti-viral protonophore and a serine protease inhibitor
CN111650307A (zh) * 2020-07-13 2020-09-11 重庆医药高等专科学校 一种同时对酒中解热镇痛类药品非法添加物定性定量检测的方法及应用
WO2022020659A1 (en) * 2020-07-23 2022-01-27 Purdue Research Foundation Ohpp-formulated niclosamide to treat sars-cov-2, other viral diseases, and cancers
CA3191727A1 (en) * 2020-08-14 2022-02-17 Mayo Foundation For Medical Education And Research Methods and materials for tissue ablation
WO2022046668A1 (en) * 2020-08-22 2022-03-03 Luc Montagnier Compositions and methods for reducing the transmissivity of illnesses
JP7885204B2 (ja) * 2020-09-08 2026-07-06 クリチテック，インコーポレイテッド ニクロサミド粒子およびその使用
CN111920824A (zh) * 2020-09-11 2020-11-13 余朝权 一种治疗伤口的中药组合物
KR102636847B1 (ko) 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
CN114246852B (zh) * 2020-09-21 2024-08-16 暨南大学 一种药物组合物在心脑血管疾病中的应用
KR102378590B1 (ko) * 2020-09-28 2022-03-24 (주)위바이오트리 난용성 약물을 포함하는 금속 (수)산화물 복합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
WO2022093871A1 (en) * 2020-10-26 2022-05-05 The Regents Of The University Of California Sars-c0v-2 inactivation by ethacridine
CN112342028B (zh) * 2020-10-28 2021-07-09 中铁建华南建设(广州)高科技产业有限公司 盾构分散剂及其制备方法和应用
WO2022091065A1 (ko) * 2020-11-02 2022-05-05 (주)아이엠디팜 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법
CN112526032B (zh) * 2020-12-28 2022-05-17 北京金城泰尔制药有限公司 聚甲酚磺醛的检测方法
WO2022147499A1 (en) * 2021-01-04 2022-07-07 Neurobo Pharmaceuticals, Inc. Method of treating viral infections with a combination of niclosamide and gemcabene
CN117062527A (zh) 2021-01-19 2023-11-14 埃里莫斯制药有限责任公司 作为冠状病毒抗病毒剂的Terameprocol和去甲二氢愈创木酸（NDGA）衍生物
CN116917267B (zh) * 2021-01-28 2025-08-12 Imd制药公司 包含卡莫司他及氯硝柳胺的共晶、包含其的药物组合物及其制备方法
CN112826795B (zh) * 2021-03-23 2022-08-30 重庆医科大学 一种载汉防己甲素脂质体制剂及其制备方法和应用
US20220304959A1 (en) * 2021-03-26 2022-09-29 First Wave Biopharma Treatment of long haulers syndrome with niclosamide
CN113368064B (zh) * 2021-06-08 2022-06-28 吉林津升制药有限公司 一种烟酸冻干粉及其制备方法
CN114134195B (zh) * 2021-11-03 2024-06-11 南方科技大学 预防前列腺癌的药剂的筛选方法、硝唑尼特在制药中的应用
WO2023096896A2 (en) * 2021-11-23 2023-06-01 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
CN113908154A (zh) * 2021-11-29 2022-01-11 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在抗银屑病及银屑病样皮肤炎症中的应用
CN114393662A (zh) * 2021-12-21 2022-04-26 凭祥青山中密度纤维板有限公司 一种环保中密度纤维板的制备方法
JP2025518339A (ja) * 2022-01-31 2025-06-12 リビオネックス・インコーポレイテッド 鉄キレート化のための新規液体製剤
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CN114796135B (zh) * 2022-03-29 2023-04-07 海南久常制药有限公司 一种硫糖铝口服制剂及其制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN114767871B (zh) * 2022-04-19 2023-04-07 中国工程物理研究院机械制造工艺研究所 介孔硅载药体系及制备方法和介孔硅载药
CN117045657B (zh) * 2022-05-12 2026-05-26 广州嘉越医药科技有限公司 一种药物组合及其应用
WO2024029639A1 (ko) * 2022-08-02 2024-02-08 제이투에이치바이오텍 주식회사 3성분 프로드럭, 이의 약학적 조성물 및 의약 용도
CN115494231A (zh) * 2022-09-02 2022-12-20 武汉三鹰生物技术有限公司 一种蛋白酶抑制剂混合物及其制备方法与应用
CN115739028B (zh) * 2022-11-26 2024-04-02 西南政法大学 一种精神活性物质吸附剂及其应用
CN116036289B (zh) * 2023-02-03 2025-05-06 中国药科大学 一种增强铁死亡治疗效果的纳米制剂及其制备方法和应用
CN116077424B (zh) * 2023-02-17 2025-06-03 重庆大学 一种多功能仿生水凝胶及其制备方法和应用
WO2024182078A1 (en) * 2023-02-28 2024-09-06 Verté Therapeutics, Llc Veterinary transdermal gel comprising ondansetron, and related methods
CN116139116A (zh) * 2023-03-30 2023-05-23 中南大学湘雅医院 氯硝柳胺在抑制急性肝衰竭中的应用
CN117045645A (zh) * 2023-05-19 2023-11-14 首药医药研究院(北京)有限公司 一种维替泊芬组合物及其应用
CN116531366B (zh) * 2023-05-23 2025-02-14 新乡医学院 罗替戈汀的药物新用途
WO2025037323A1 (en) * 2023-08-12 2025-02-20 Pavan Kumar Kothapuvari Pharmaceutical compositions for treatment of dry eye disease and associated disorders
CN117147512A (zh) * 2023-08-23 2023-12-01 河北科技大学 一种快速检测酒类中甜蜜素的方法
KR102921518B1 (ko) * 2023-09-04 2026-02-03 숭실대학교 산학협력단 니클로사마이드 및 피콜린산으로 이루어진 공결정, 이의 제조방법 및 이의 의학적 용도
CN117180223A (zh) * 2023-09-25 2023-12-08 浙江大学医学院附属第一医院 一种负载硝呋齐特的巨噬细胞递药系统及其应用
CN117357509B (zh) * 2023-09-28 2026-04-03 华中科技大学 一种吲哚菁绿稳定的CuET纳米颗粒、纳米颗粒分散液及其制备方法和应用
CN117883443A (zh) * 2023-12-12 2024-04-16 中国海洋大学 吡罗克酮乙醇胺盐在制备治疗胃肠道疾病的药物中的应用
CN117899225A (zh) * 2024-01-19 2024-04-19 芮城绿曼生物药业有限公司 一种增强免疫力的兽用抗菌注射剂、制备方法及应用
TW202610087A (zh) * 2024-04-12 2026-03-01 美商安達偉勝公司 包含3-胺基-2-丁醇之調配物及其於電氣及電子應用之用途
CN118680976A (zh) * 2024-06-21 2024-09-24 湖南九安禾生物科技有限公司 一种槟榔提取物在制备抗抑郁药物中的应用
CN119055625B (zh) * 2024-07-23 2025-09-09 湖北工业大学 Tiratricol在制备抗ADV7病毒药物中的应用
CN120204184A (zh) * 2025-02-17 2025-06-27 深圳市第三人民医院(深圳市肝病研究所) 阿米替林和/或其衍生物的应用、结核分枝杆菌抑制剂和药物组合物
CN119700664B (zh) * 2025-02-28 2025-06-20 山东新时代药业有限公司 含有活性成分琥珀酸普芦卡必利的注射液及其制备方法
CN120713881B (zh) * 2025-08-21 2025-12-05 南方科技大学 氯硝柳胺在治疗器官移植排斥反应中的应用
CN121243140A (zh) * 2025-11-06 2026-01-02 中国人民解放军海军军医大学 索法酮在制备防护放射性肠损伤药物中的应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3079297A (en) 1960-05-31 1963-02-26 Bayer Ag Method of combating gastropods
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
NZ223200A (en) 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
DE4005528C2 (de) 1990-02-22 1998-01-15 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung für Medien
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
EP0504459B1 (de) 1991-03-21 1996-06-05 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
DE59108798D1 (de) 1991-11-07 1997-08-28 Ritzau Pari Werk Gmbh Paul Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
ATE121971T1 (de) 1991-11-07 1995-05-15 Ritzau Pari Werk Gmbh Paul Flüssigkeitszerstäubervorrichtung.
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
ES2120471T3 (es) 1993-12-17 1998-11-01 Pari Gmbh Spezialisten Fuer Effektive Inhalation Boquilla de pulverizacion.
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5663155A (en) * 1994-11-30 1997-09-02 The University Hospital Compositions for the treatment of parasitic infections
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
EP0821970A1 (en) 1996-08-02 1998-02-04 Edward Henri Charles Verhaeren Carrier composition for influencing the tight junction permeability
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5905090A (en) 1998-04-29 1999-05-18 Italfarmaco S.P.A. Analogues of the active metabolite of leflunomide
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US7635722B1 (en) 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US6653309B1 (en) 1999-04-26 2003-11-25 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme technical field of the invention
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
AU2001260083A1 (en) * 2000-05-26 2001-12-03 Dr. Reddy's Research Foundation New pharmaceutical composition and the process for its preparation
WO2002049632A1 (en) 2000-12-18 2002-06-27 Institute Of Medicinal Molecular Design. Inc. Inhibitors against the production and release of inflammatory cytokines
CN1289072C (zh) 2000-12-22 2006-12-13 石原产业株式会社 苯胺衍生物或其盐以及含有它们的细胞因子产生抑制剂
US6862890B2 (en) 2001-01-30 2005-03-08 Board Of Regents, University Of Texas System Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040022861A1 (en) 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040071757A1 (en) 2001-11-20 2004-04-15 David Rolf Inhalation antiviral patch
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2004006906A2 (en) 2002-07-15 2004-01-22 Combinatorx, Incorporated Methods for the treatment of neoplasms
WO2004064808A1 (en) 2003-01-15 2004-08-05 Dow Global Technologies Inc. Drug particles obtained by freezing onto a cold surface
TWI343810B (en) 2003-05-28 2011-06-21 Nat Health Research Institutes A pharmaceutical composition for inhibiting coronavirus
WO2005001052A2 (en) * 2003-06-06 2005-01-06 University Of Massachusetts Modulation of apoptosis
US7249224B2 (en) 2003-08-05 2007-07-24 Newisys, Inc. Methods and apparatus for providing early responses from a remote data cache
DE10340277B4 (de) 2003-08-29 2006-11-23 Bio-Gate Bioinnovative Materials Gmbh Körperpflegemittel mit Silber-Agglomeraten
US7691578B2 (en) 2004-07-07 2010-04-06 Dana-Farber Cancer Institute, Inc. Methods and compositions for treating obesity
CN1626506A (zh) 2004-08-10 2005-06-15 李志良 高纯度、高收率氯硝柳胺的制备
EP1789018A1 (en) 2004-08-27 2007-05-30 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
US20100041657A1 (en) 2005-05-11 2010-02-18 Novo Nordick A/S Haloalkylsulfone substituted compounds useful for treating obesity and diabetes
JP2008545677A (ja) 2005-05-23 2008-12-18 ノボ ノルディスク アクティーゼルスカブ 新規なハロアルコキシ置換サリチル酸アニリド
GB0607534D0 (en) 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
EP2049137A4 (en) 2006-08-08 2013-05-01 Univ California SALICYLANILIDES AS AMPLIFIERS OF THE ORAL RELEASE OF THERAPEUTIC PEPTIDES
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US8262657B2 (en) 2007-08-16 2012-09-11 Nutek Orthopaedics, Inc. External fixation apparatus with adjustable pin clamping means and convergent bone pins
BRPI0822026B8 (pt) 2008-01-10 2021-05-25 Evonik Roehm Gmbh preparação farmacêutica ou nutracêutica, comprimido, gelatina ou cápsula de hpmc, e uso de uma ou uma mistura de uma pluralidade de polímeros ou copolímeros
EP2252275B1 (en) 2008-02-13 2017-11-29 Board of Regents, The University of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
US20100215782A1 (en) 2008-10-22 2010-08-26 Metaproteomics, Llc Novel mitochondrial uncoupling methods and compositions for enhancing adipocyte thermogenesis
CU23701A1 (es) * 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
CN101601670B (zh) 2009-06-30 2014-06-04 青岛蔚蓝生物股份有限公司 一种宠物用复方氯硝柳胺驱虫片剂及其制备方法
KR100990110B1 (ko) 2009-08-18 2010-10-29 엘지전자 주식회사 태양 전지
WO2011035321A1 (en) 2009-09-21 2011-03-24 Duke University Treatment of wnt/frizzled-related diseases
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
GB201015079D0 (en) 2010-09-10 2010-10-27 Helperby Therapeutics Ltd Novel use
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
JP5770304B2 (ja) 2010-11-16 2015-08-26 ユニバーシティ・オブ・メディシン・アンド・デンティストリー・オブ・ニュージャージーＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｅｄｉｃｉｎｅ Ａｎｄｄｅｎｔｉｓｔｒｙ Ｏｆ Ｎｅｗ Ｊｅｒｓｅｙ 安全な化学的ミトコンドリア脱共役剤を用いたｉｉ型糖尿病及び糖尿病関連疾患の治療
WO2012143377A1 (en) 2011-04-18 2012-10-26 Max-Delbrück-Centrum für Molekulare Medizin Niclosamide for the treatment of cancer metastasis
WO2012154944A2 (en) 2011-05-10 2012-11-15 Stc.Unm Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits
CA2841358A1 (en) * 2011-07-15 2013-01-24 S.L.A. Pharma Ag Pharmaceutical compositions for rectal administration
CN104602682B (zh) 2012-05-08 2018-12-14 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
WO2014023329A1 (en) 2012-08-06 2014-02-13 Life And Brain Gmbh Niclosamide and its derivatives for use in the treatment of solid tumors
CN102861014A (zh) * 2012-10-16 2013-01-09 天津必佳药业集团有限公司 一种畜禽用抗蠕虫病复方氯硝柳胺片及其制备方法
CN103891720B (zh) * 2012-12-27 2016-02-17 陕西汤普森生物科技有限公司 一种含有螺枯威的复配杀螺组合物
CA2898113C (en) 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
US9138425B2 (en) * 2013-03-12 2015-09-22 Patheon Inc. Drug delivery system to increase bioavailability
BR112015006499A2 (pt) 2013-04-23 2017-07-04 Zx Pharma Llc composição de óleo de horlelã-pimenta de liberação controlada microparticulada com revestimento entérico e métodos relacionados
US9669036B2 (en) 2013-05-14 2017-06-06 The University Of Chicago Modulation of reactivation of a latent virus
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
EP3027755B1 (en) 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
EP3062808B1 (en) 2013-10-28 2021-09-29 The Regents of the University of California Treatment of metastatic prostate cancer
JP7066321B2 (ja) 2014-01-10 2022-05-13 アヴァリン ファーマ インク． エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
CN103751854B (zh) 2014-01-20 2015-08-26 瞿介明 抗菌医用导管
PL3590962T3 (pl) 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
JP6047203B2 (ja) 2015-02-20 2016-12-21 セルセウティックス コーポレイション 消化管の炎症性疾患の予防および／または治療のための宿主防御タンパク質（ｈｄｐ）模倣薬
US9566399B1 (en) 2015-04-14 2017-02-14 Clempharma LLC Deep lung alveolar aerosol targeted drug delivery
BR112017023351B1 (pt) 2015-05-01 2023-11-28 Board Of Regents, The University Of Texas System Composição farmacêutica e uso da composição farmacêutica
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105063018A (zh) * 2015-08-31 2015-11-18 山西大学 一种从葡萄成熟果实中提取总rna的方法
UA125747C2 (uk) 2015-09-01 2022-06-01 Фьост Вейв Байо, Інк. Способи та композиції для лікування станів, пов'язаних із аномальною запальною відповіддю
EP3168211A1 (en) 2015-11-10 2017-05-17 Westfälische Wilhelms-Universität Münster Pharmaceutical co-crystals of niclosamide
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
WO2017223491A1 (en) 2016-06-23 2017-12-28 Health Research, Inc. Pharmaceutical compositions with antiflaviviral activity
WO2018017426A1 (en) 2016-07-16 2018-01-25 Florida State University Research Foundation, Inc. Compounds and methods for treatment and prevention of flavivirus infection
KR101928543B1 (ko) 2017-01-09 2018-12-13 사단법인 분자설계연구소 니클로사마이드를 함유하는 Axin-GSK3 단백질 결합 관련 질환 치료용 약학조성물
WO2018136559A1 (en) 2017-01-17 2018-07-26 The Regents Of The University Of California Methods for treating flaviviruses and zika infections
EP3576755B1 (en) 2017-02-02 2026-07-01 McMaster University BICARBONATE AS AN ANTIMICROBIAL ENHANCER
BR112019019519A2 (pt) 2017-03-21 2020-04-22 Novalead Pharma Inc agente terapêutico para a inibição de fosfodiesterase e seus distúrbios relacionados
CN110730674B (zh) 2017-04-18 2022-02-01 励志私人有限公司 干粉吸入器和用于干粉吸入器的间隔装置
US11807906B2 (en) 2017-05-08 2023-11-07 The Governors Of The University Of Alberta Peroxisome biomarkers in HIV disease progression and peroxisome activating drugs for HIV treatment
WO2018213834A1 (en) 2017-05-19 2018-11-22 Pneuma Respiratory, Inc. Dry powder delivery device and methods of use
US20200206139A1 (en) 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
WO2019051440A1 (en) 2017-09-11 2019-03-14 Board Of Regents, The University Of Texas System MEDICAMENT COMPOSITIONS COMPRISING POROUS MEDIA PRODUCED BY THERMAL OR FUSION-BASED METHODS
CA3085943A1 (en) 2017-12-21 2019-06-27 Civitas Therapeutics, Inc. Surfactant formulations for inhalation
WO2019147626A1 (en) 2018-01-23 2019-08-01 The Trustees Of Columbia University In The City Of New York Activation of mitochondrial uncoupling as a therapeutic intervention
WO2019217164A1 (en) 2018-05-09 2019-11-14 Reyoung Corporation Compositions and methods for treating cancer and other diseases
US11166926B2 (en) 2018-08-08 2021-11-09 The Hospital For Sick Children Compositions and methods for protecting a host from enteric toxigenic pathogens
PH12022550448A1 (en) 2019-08-23 2022-12-12 Daewoong Pharmaceutical Co Ltd Niclosamide delayed-release composition and antiviral use thereof
US20210114973A1 (en) 2019-10-18 2021-04-22 First Wave Bio, Inc. Pharmaceutical formulations
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11045434B1 (en) 2020-04-01 2021-06-29 UNION therapeutics A/S Niclosamide formulations for treating disease

Also Published As

Publication number Publication date
TN2018000069A1 (en) 2019-07-08
PE20181295A1 (es) 2018-08-07
US20200147012A1 (en) 2020-05-14
MX2023014409A (es) 2023-12-13
EP3344274A1 (en) 2018-07-11
US10849867B2 (en) 2020-12-01
US20170056347A1 (en) 2017-03-02
CN109562137A (zh) 2019-04-02
IL257801A (en) 2018-04-30
AU2016315852B2 (en) 2023-06-15
KR20180080189A (ko) 2018-07-11
US20200147013A1 (en) 2020-05-14
US20200276140A1 (en) 2020-09-03
US10292951B2 (en) 2019-05-21
EP3344274A4 (en) 2019-05-22
CO2018003465A2 (es) 2018-08-31
US10772854B2 (en) 2020-09-15
UA125747C2 (uk) 2022-06-01
JP6955648B2 (ja) 2021-10-27
BR112018004069A2 (pt) 2021-07-13
JP2018529762A (ja) 2018-10-11
WO2017040864A1 (en) 2017-03-09
US10912746B2 (en) 2021-02-09
US11793777B2 (en) 2023-10-24
US20200268694A1 (en) 2020-08-27
AU2023203354A1 (en) 2023-07-06
US10744103B2 (en) 2020-08-18
US10799468B2 (en) 2020-10-13
US20220000812A1 (en) 2022-01-06
SG10201914118SA (en) 2020-02-27
CR20180185A (es) 2018-12-06
CA2997136A1 (en) 2017-03-09
MX2022014310A (es) 2022-12-07
HK1258048A1 (zh) 2019-11-01
MX2018002586A (es) 2020-11-24
US20240074995A1 (en) 2024-03-07
PH12018500448A1 (en) 2018-09-24
JP7189983B2 (ja) 2022-12-14
US20210401784A1 (en) 2021-12-30
CL2021000622A1 (es) 2021-10-01
US20190298670A1 (en) 2019-10-03
US20200197340A1 (en) 2020-06-25
AU2016315852A1 (en) 2018-03-22
JP2021098727A (ja) 2021-07-01
US10905666B2 (en) 2021-02-02
US20200197339A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
PH12018500448A1 (en) Methods and compositions for treating conditions associated with an abnormal inflammatory responses
EA201792047A1 (ru) Новые соединения
SA522433000B1 (ar) مركبات فلورو ألكيل-أوكساديازول واستخداماتها
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
EA201990019A1 (ru) Соединения и композиции для подавления активности shp2
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
EA201792354A1 (ru) Композиции обетихолевой кислоты и способы применения
EA201591535A1 (ru) Замещенные производные 3-фенилпропиламина для лечения офтальмологических заболеваний и расстройств
JOP20190193A1 (ar) ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان
EA201790660A1 (ru) Ингибитор киназ
EA201790492A1 (ru) СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
MX2020000349A (es) Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2).
EA201691881A1 (ru) Новые соединения
EA201500816A1 (ru) Замещенные бициклические дигидропиримидиноны и их применение в качестве ингибиторов активности нейтрофильной эластазы
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
JOP20200100A1 (ar) مشتقات بيرازولو-بيرولو-بيريميدين-ديون جديدة كمثبِّطات لـ p2x3
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
EA201790253A1 (ru) Ингибиторы альдостеронсинтазы
CY1123880T1 (el) Καινοτομοι 5-ητ2 ανταγωνιστες
EA201492283A1 (ru) Замещенные соединения пиразола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
BR112015019919A2 (pt) compostos bicíclicos